BC PharmaCare Review Questionnaires for Epclusa (Once on the page, scroll down until you see a colourful table. Links to questionnaires for Epclusa input are at the very bottom of the page/colourful table.)
Epclusa (generic name sofosbuvir / velpatasvir) is being considered for BC PharmaCare coverage. As part of this process, hep C patients, caregivers, and patient groups in BC have the opportunity to share their opinions and perspectives about hepatitis C treatments and Epclusa with the decision makers.
If you are interested in grabbing this opportunity, the link above will take you to the questionnaires. The above link will also take you to BC PharmaCare’s Epclusa Information sheet and to information about BC PharmaCare’s approval process.
The questionnaires will ONLY remain open until Wednesday, September 21, AT MIDNIGHT
Adding Your Voice to the BC PharmaCare Coverage Review for Epclusa
If you answer yes to any of the following questions, you are encouraged to give your input:
- Do you have hep C?
- Are you a caregiver/loved one to someone who has hep C?
- Does your patient group represent patients who have hep C AND have you registered with PharmaCare to give input? (Learn more about registering your organization).
Epclusa is the first pan-genotypic hepatitis C treatment* to be approved for use in Canada against all six hep C virus types. It is a short-course (12 weeks), interferon-free, hepatitis C treatment that can be prescribed with or without ribavirin. It is one pill taken once a day. With or without ribavirin, it cured 83-98% of patients in clinical trials, and cured 94% of those with moderate to severe liver cirrhosis.
The Importance of Epclusa
Epclusa, the first hep C pan-genotypic treatment, is important as it has the power to make hep C treatment much easier than it is now. As Dr. Jordan Feld, a liver specialist at Toronto Western Hospital, explained, a treatment that can be used for every virus type “…eliminates the need for [virus type/genotype] testing, which often delayed treatment and can be difficult to access for those living in rural or remote regions of the country….” (Ubelacker, The Canadian Press)
Also, Epclusa is the first treatment for patients with a hep C genotype 2 or 3 infection that doesn’t need ribavirin to achieve best treatment results.
More Information about Epclusa
- Epclusa: An Information Sheet for an Approved Treatment
- Epclusa: Approved treatment for all hep C types
- Hepatitis C treatment Epclusa approved in Canada—key information by CATIE
- Gilead Canada‘s press release about receiving a Notice of Compliance (NOC) from Health Canada for Epclusa
- Epclusa’s Canadian product monograph by Gilead
Take the time to voice your opinion and help advocate for a better tomorrow!
*A pan-genotypic treatment is a treatment able to cure all six of the hep C virus types with high success rates against all six.